AVIVA Biosciences Revenue and Competitors

AVIVA Biosciences invents devices and assays to advance the study of eukaryotic cells. AVIVA serves as a contract research organization providing safety screening with emphasis on ion channels. As a CRO, AVIVA provides safety screening specializing in cardiovascular mechanics, electrophysiology, and safety. All assays are customizable to match the needs of the customer. Standard formats include Langendorff, Purkinje, Trabeculae, myocytes, and clonal lines from various species including living human tissue, and with assays including action potential prolongation, ion channel effect profiling, ion channel assays such as hERG, contraction, viability, valvulopathy, and others. AVIVA has launched a proprietary instrument and filter array system engineered to separate mixed cell populations based on cell size, shape and conformity. The RedSift Filter System filters whole blood, bone marrow, or other biological fluids, to permit erythrocytes, thrombocytes, plasma, and cell fragments to pass through while retaining all leukocytes including lymphocytes, and any rare cells in the circulation. The gentle process of cell recovery avoids harsh chemicals and gradient centrifugation, consistently recovering >90% of total nucleated cells in a sample. This technology is useful for various cytometry applications, new assay development, working with small volumes of animal or human blood, and analyzing rare cell populations, including CTCs and rare cells. Sealchip16, the first commercialized voltage clamp biochip capable of performing gigaohm seals, became the gold standard for automated voltage clamp. This product was upgraded in late 2003, and in 2010 the Sealchip16 was released to provide better success rates with certain cell-types. See the link below for more information on AVIVA's SealChip and tutorials on PatchXpress, Cell Isolation, and Voltage Clamp: http://www.avivabio.com/toolsdocs/